

MEDIA RELEASE

Cordlife Publishes Study Confirming Superiority of Strategic Partner's Stem Cell Growth Media

- The paper is the result of a three-year study conducted by Cordlife and CellResearch Corporation (“CRC”), Cordlife’s strategic partner and expert in cell biology, to study and define the effects of using different culture media and extraction methods to get mesenchymal stromal cells (“MSC”) from cryopreserved umbilical cords.
- The study proves and confirms that CRC’s patented PTT-6™ culture media accelerates the growth of MSC at a rate that is almost twice as fast as conventional culture media.
- Cordlife is the only cord blood bank licensed to bank cord lining, a biological source patented by CRC.

SINGAPORE, 1 November 2022 – Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), a Singapore Exchange mainboard listed company, is pleased to announce the successful publication of its study “Deriving Mesenchymal Stromal Cells from Umbilical Cord Lining and Wharton’s Jelly: A Comparative Study of Extraction Methods and Culture Media” in BioProcess International, an internationally acclaimed magazine devoted to the development, scale-up, and manufacture of biotherapeutics and bio-diagnostics. The full study can be accessed here: <https://bioprocessintl.com/manufacturing/cell-therapies/deriving-mesenchymal-stromal-cells-from-umbilical-cord-lining-and-whartons-jelly-a-comparative-study-of-extraction-methods-and-culture-media/>.

This study is the result of three years of extensive research conducted in collaboration with CellResearch Corporation Pte. Ltd, Cordlife’s strategic partner and cell biology experts. CRC’s patented PTT-6™ culture media contains less serum, which provides consistency in performance and is suitable for large-scale current good manufacturing practice (“cGMP”) manufacture of MSC-based therapy products by the European Medicines Agency (“EMA”) and the U.S. Food and Drug Administration (“FDA”).

The findings of the study demonstrated that MSCs can be successfully extracted using PTT-6™ from cryopreserved tissues taken from two major regions of the umbilical cord – the cord lining and Wharton’s jelly. Explant and enzymatic digestion, both methods of stem cell extraction, had no effect on MSC extraction efficiency. The comparative study found that PTT-6™ boosts MSC proliferation at nearly twice the rate of conventional culture media. Furthermore, despite repeated passaging and culturing, MSCs cultured in PTT-6™ retain high cell purity, potency, and genomic stability.



The study also discusses the numerous advantages of umbilical cord-derived MSCs in the healing of chronic inflamed wounds. This points to the umbilical cord as a readily available source of MSCs that poses no ethical concerns because they are normally discarded as medical waste after childbirth. Besides that, as the healthcare industry shifts towards preventive care and early detection, umbilical cord-derived MSCs will play an important role in not only potentially treating diseases but also slowing their progression or even delaying their onset entirely. Several clinical trials are being conducted around the world to discover new medical treatments and cures for common diseases such as coronary artery disease, cancer and blood, immune, and metabolic disorders using stem cells.¹ Cordlife Group is honoured to be a part of the future of medicine and healthcare, which has the potential to improve lives.

Ms Tan Poh Lan, Group Chief Executive Officer and Executive Director of Cordlife Group Limited, said, “This study shows how well our strategic partnership with CRC has worked. Their impressive knowledge of cell biology and stem cell technology complements our 21 years of experience in stem cell banking. The long-term study shows how important it is to keep the properties of umbilical cord-derived MSCs by using the right extraction and culture media in order to get the most out of them.”

Cordlife has an exclusive licence to offer cord lining banking using CRC’s technology in all markets where it operates.

End

ABOUT CELLRESEARCH CORPORATION PTE LTD

CellResearch Corporation (CRC) was founded in 2002 as a contract research provider focusing on skin cells. In 2004, the company made the discovery that the umbilical cord lining of mammals was an abundant source of both mesenchymal and epithelial stem cells. Today, the company owns this technology through a family of patents and holds the rights to commercialise this technology in most major markets globally through several subsidiaries.

CellResearch Therapeutics has developed CorLiCyte®, a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions. In addition to diabetic foot ulcer indications, CRC is pursuing a range of potential indications at pre-clinical stage such as osteoarthritis, venous leg ulcers, chronic inflammatory and autoimmune conditions.

CellResearch Consumer Health (formerly known as CALECIM® Cosmeceuticals) is a wholly owned subsidiary of CRC and produces an innovative range of skin and hair care regimes using cord lining stem cell media to power its products. It is used in medical hair and aesthetic clinics for in-office treatments and as part of an at-home anti-aging skincare regime. It is distributed globally

¹ ClinicalTrials.gov website.

<https://clinicaltrials.gov/ct2/show/NCT01946048?term=cord%2Bblood&cond=Ischemic%2BHeart%2BDisease&draw=2&rank=2>. Accessed October 12, 2022.



through over 600 aesthetic physicians and online via its own website. It has a key distribution partnership with Menarini Group across Southeast Asia.

ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia, and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening.

Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. All of the Group’s facilities are accredited by the Association for the Advancement of Blood & Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available, and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India, Cordlife Hong Kong, and Healthbaby Hong Kong are all accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India is one of the only two medical laboratories in West Bengal to be holding accreditation from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr. Kamal Samuel / Ms. Urvija Diwan

OFFICE : (65) 9229 4410 / (65) 9371 1683

EMAIL : kamal@financialpr.com.sg / urvija@financialpr.com.sg

*For CellResearch enquiries, please contact: Xavier Simpson
(xaviersimpson@cellresearchcorp.com)*